To view this email as a web page, go here.

Message below is a paid advertisement. Content is provided by the sponsor.

 

Discover the difference of 12-week* flea and tick protection with Bravecto®
Bravecto
1 Dose. 12 Weeks.*
Discover the Difference.
SEE THE DIFFERENCE 12-WEEK* FLEA AND TICK PROTECTION WITH BRAVECTO® CAN MAKE IN YOUR CLINIC. Discover Bravecto
Better pet owner adherence and more visits are just a few ways Bravecto® is helping make a difference at veterinary clinics. That’s because only Bravecto has killing fleas and ticks all taken care of for 12 weeks* with just one convenient chew.1
Start recommending 12-week* prescription-only protection to pet owners at your clinic that:
Bullet-point Lasts nearly 3X longer than any other chew
Bullet-point Kills 100% of fleas and ticks within 12 hours2,3
Bullet-point Is proven safe and effective for breeding, pregnant and lactating dogs1
Discover the difference 12-week* prescription-only Bravecto can make for your clinic.
THE 12-WEEK* DIFFERENCE
How can 12-week* protection make a difference for your clinic? Find out now.
Discover Bravecto
MSD
*Bravecto kills fleas, prevents flea infestations, and kills ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks and also kills lone star ticks for 8 weeks.
IMPORTANT SAFETY INFORMATION: The most common adverse reactions recorded in clinical trials were vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. Bravecto has not been shown to be effective for 12-weeks’ duration in puppies less than 6 months of age. Bravecto is not effective against lone star ticks beyond 8 weeks after dosing.
VIEW PRESCRIBING INFORMATION
References: 1. Bravecto [prescribing information]. Madison, NJ: Merck Animal Health; 2014. 2. Burgio et al. Parasites & Vectors (2016) 9:626. 3. Taenzler et al. Parasites & Vectors (2014) 7:567.
To opt-out of further Merck Animal Health communications click here.
Copyright © 2017 Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co. Inc. All rights reserved.
US/BRV/1216/0111